World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Medicine

D-Index
151
Citations
101465
World Ranking
1105
National Ranking
52

Wolfgang Wick publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Wolfgang Wick sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 877 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Wolfgang Wick D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Wolfgang Wick sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 151 D-Index — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Wolfgang Wick is affiliated with the German Cancer Research Center in Germany. The primary focus of their research lies within the broad field of Medicine, with significant contributions in subfields such as Genetics, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Pulmonary and Respiratory Medicine, and Oncology.

The scientist's work prominently addresses the diagnosis and treatment of gliomas, a major topic within their portfolio, alongside other key areas including brain metastases and treatment, radiomics and machine learning in medical imaging, meningioma and schwannoma management, CAR-T cell therapy research, immunotherapy and immune responses, and cancer genomics and diagnostics.

Wolfgang Wick has published extensively in several academic venues, with a notable number of publications in:

  • Neuro-Oncology
  • Cancer
  • Neuro-Oncology Advances
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Acta Neuropathologica

Their recent scholarly output includes these papers:

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020, Nature Reviews Clinical Oncology)
  • How to use and assess qualitative research methods (2020, Neurological Research and Practice)
  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions (2020, Neuro-Oncology)
  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022, Annals of Oncology)
  • Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (2023, New England Journal of Medicine)

Collaborative efforts form an integral part of their research, with frequent co-authors including:

  • Felix Sahm
  • Andreas von Deimling
  • Martin Bendszus
  • Michael Weller
  • Michael Platten

Best Publications

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • DNA methylation-based classification of central nervous system tumours

    David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt

  • Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

    Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson

  • Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

    Dominik Sturm;Hendrik Witt;Hendrik Witt;Volker Hovestadt;Dong Anh Khuong-Quang

  • An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

    Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott

  • Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge

    Spyridon Bakas;Mauricio Reyes;Andras Jakab;Stefan Bauer

  • Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

    Christian Hartmann;Christian Hartmann;Jochen Meyer;Jörg Balss;David Capper

  • Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

    Wolfgang Wick;Michael Platten;Christoph Meisner;Joerg Felsberg

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

    Michael Weller;Martin van den Bent;Matthias Preusser;Emilie Le Rhun

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Brain tumour cells interconnect to a functional and resistant network

    Matthias Osswald;Matthias Osswald;Erik Jung;Erik Jung;Felix Sahm;Felix Sahm;Gergely Solecki;Gergely Solecki

  • Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas

    Christian Hartmann;Christian Hartmann;Bettina Hentschel;Wolfgang Wick;Wolfgang Wick;David Capper

  • Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

    James R. Perry;Normand Laperriere;Christopher J. O'Callaghan;Alba A. Brandes

  • Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

    Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin

  • Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

    Monika E. Hegi;Lili Liu;James G. Herman;Roger Stupp

  • European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

    Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp

  • NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

    Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

    Michael Weller;Roger Stupp;Guido Reifenberger;Alba A. Brandes

  • How to use and assess qualitative research methods.

    Loraine Busetto;Wolfgang Wick;Wolfgang Wick;Christoph Gumbinger

Frequent Co-Authors

Michael Weller
Michael Weller University of Zurich
Felix Sahm
Felix Sahm University Hospital Heidelberg
Andreas von Deimling
Andreas von Deimling Heidelberg University
Martin Bendszus
Martin Bendszus University Hospital Heidelberg
Stefan M. Pfister
Stefan M. Pfister German Cancer Research Center
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
David Capper
David Capper Charité - University Medicine Berlin
Roger Stupp
Roger Stupp Northwestern University
Guido Reifenberger
Guido Reifenberger Heinrich Heine University Düsseldorf
Sabine Heiland
Sabine Heiland University Hospital Heidelberg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of healthcare careers that don’t always require traditional paths. For those interested in the administrative side, medical billing and coding schools online provide flexible options and are vital in ensuring healthcare facilities run smoothly.

Those looking to enter the nursing field can benefit from nursing schools that don't require teas, which can help bypass certain exam barriers and streamline the admissions process. If management and leadership are your goals, healthcare administration programs online can help you gain the necessary skills efficiently.

Nurses seeking to advance their qualifications can take advantage of rn to fnp bridge programs designed to fast-track career progression from registered nurse to family nurse practitioner. These alternative pathways reflect the growing flexibility and opportunity within the US healthcare education system, making it easier than ever to find a route that matches your career goals.

Best Scientists Citing Wolfgang Wick

Trending Scientists

Recently Published Articles